Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AXON Axovant Sciences Ltd. daily Stock Chart
AXON [NASD]
Axovant Sciences Ltd.
Healthcare | Biotechnology | United Kingdom
financial highlights | statements
Index- P/E- EPS (ttm)-2.09 Insider Own0.60% Shs Outstand110.83M Perf Week-8.09%
Market Cap629.51M Forward P/E- EPS next Y-2.07 Insider Trans0.00% Shs Float31.88M Perf Month-78.22%
Income-212.20M PEG- EPS next Q-0.56 Inst Own33.10% Short Float17.19% Perf Quarter-75.52%
Sales- P/S- EPS this Y-29.50% Inst Trans0.15% Short Ratio2.83 Perf Half Y-74.76%
Book/sh1.68 P/B3.38 EPS next Y-2.50% ROA- Target Price13.89 Perf Year-58.02%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.51 - 27.98 Perf YTD-54.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.70% Beta-
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low3.09% ATR1.27
Employees69 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)24.74 Volatility6.77% 8.29%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.74 Prev Close5.80
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume1.94M Price5.68
Recom2.40 SMA20-33.51% SMA50-64.77% SMA200-68.36% Volume1,438,611 Change-2.07%
Sep-27-17Downgrade Robert W. Baird Outperform → Neutral $29 → $6
Sep-26-17Reiterated Chardan Capital Markets Sell $8 → $3
Sep-26-17Downgrade Piper Jaffray Overweight → Neutral
Sep-08-17Resumed Evercore ISI Outperform $30
Jul-11-17Initiated Jefferies Buy
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Oct-20-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-18-17 08:42AM  Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher Zacks -6.07%
08:32AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9% Zacks
Oct-17-17 08:39AM  uniQure (QURE) in Focus: Stock Moves 11.9% Higher Zacks
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-11-17 08:37AM  Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher Zacks
Oct-10-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-06-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -10.98%
Oct-03-17 01:41PM  Roivant Wins A Battle Forbes
11:25AM  Biotech Can Keep Rallying Through The End Of The Year Barrons.com
09:53AM  After Intepirdine Flunked in Alzheimers Disease, Is Axovant Sciences a Buy? Motley Fool
Sep-30-17 12:31AM  [$$] How a Failed Alzheimers Drug Stung Some Large Hedge Funds The Wall Street Journal
Sep-29-17 05:05PM  [$$] How a Failed Alzheimer's Drug Stung Some Large Hedge Funds The Wall Street Journal
08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Sep-28-17 12:58PM  Here Is What Vivek Ramaswamy Wrote To His Employees After Axovant's Drug Failed Forbes
Sep-27-17 04:33PM  Snapback Rally Sends Axovant Sciences 10% Higher Today Motley Fool +10.43%
09:49AM  Company News For Sep 27, 2017 Zacks
09:46AM  Axovant Rises After Tuesday's Plunge - Biotech Movers TheStreet.com
08:20AM  Today's Research Reports on Stocks to Watch: Axovant and Moleculin ACCESSWIRE
12:39AM  [$$] Why Biotechs Retreat Wont Be as Dramatic This Time The Wall Street Journal
12:38AM  [$$] Axovant Says Experimental Drug Failed Trials in Treating Alzheimers Disease The Wall Street Journal
Sep-26-17 06:00PM  Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now? Motley Fool -73.90%
04:30PM  Why Axovant Sciences, The Habit Restaurants, and Silvercorp Metals Slumped Today Motley Fool
04:26PM  Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers TheStreet.com
04:22PM  This Biotech Craters 70% On Late-Stage Alzheimer's Drug Failure Investor's Business Daily
04:04PM  Axovant, Genocea Plunge into Tuesdays 52-Week Low Club 24/7 Wall St.
03:00PM  Biotech's Boy Wonder Calls Alzheimer's Drug His 'Single Greatest Failure' Forbes
01:27PM  Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why Zacks
12:50PM  Axovant Alzheimer's drug fails late-stage trial CNBC Videos
12:35PM  Roivant subsidiary sees stock tumble on negative Alzheimers results American City Business Journals
12:24PM  Is Axovant Sciences Stock a Bad-News Buy? Motley Fool
10:01AM  [$$] Why Biotech's Retreat Won't Be as Dramatic This Time The Wall Street Journal
08:55AM  Axovant's stock is crashing after failing a key drug trial Business Insider
08:50AM  Why Axovant Is Getting Absolutely Crushed 24/7 Wall St.
08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:59AM  [$$] Axovant Alzheimer's drug fails in clinical trials Financial Times
07:32AM  UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer's treatment fails to meet primary goals MarketWatch
07:18AM  A biotech founded by a 32-year-old just failed a key Alzheimer's drug trial Business Insider
07:10AM  Axovant's Alzheimer's drug fails late-stage trial Reuters
07:00AM  Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease PR Newswire
Sep-25-17 05:00AM  Alzheimers Drug May Mean $2 Billion Opportunity for Axovant Bloomberg
Sep-22-17 01:16PM  Traders expect an 80% move for this hot biotech stock in the next month CNBC
08:40AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
Sep-21-17 05:31PM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
07:55AM  Venturing Boldly Into Neuroscience Forbes
Sep-19-17 08:35AM  Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2% Zacks +6.08%
03:00AM  Axovant Sciences Shows Rising Price Performance With Jump To 93 RS Rating Investor's Business Daily
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -7.74%
03:00AM  Axovant Sciences Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-11-17 08:40AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks +5.47%
Sep-06-17 01:35PM  Why September Will Be A 'Make Or Break' Month For These Biotechs Investor's Business Daily
09:23AM  Today's Bell Ringer, September 6, 2017 CNBC Videos
07:00AM  Axovant to Present at Two Upcoming Investor Conferences PR Newswire
Aug-30-17 10:56AM  QVT Financials Investments, Performance, Letters Insider Monkey
07:40AM  Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma ACCESSWIRE
Aug-22-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-21-17 04:15PM  Axovant to Move Stock Exchange Listing to Nasdaq PR Newswire
Aug-18-17 08:50AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-10-17 02:00PM  Roivant's Billion-Dollar Haul Shouldn't Buy Off Skepticism Bloomberg
08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Aug-09-17 06:41PM  [$$] SoftBank Leads $1.1 Billion Investment in Roivant Sciences The Wall Street Journal
10:43AM  A 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life Business Insider
09:45AM  Biotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups Forbes
Aug-07-17 11:57PM  Axovant reports 1Q loss Associated Press
07:10AM  Axovant reports 1Q loss Associated Press
07:00AM  Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates PR Newswire
Jul-26-17 02:04PM  Will Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug? Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-18-17 08:32AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
Jul-17-17 07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jul-10-17 08:45AM  Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman PR Newswire
08:00AM  Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference PR Newswire
Jun-29-17 08:15AM  Earnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings Accesswire
Jun-28-17 08:21AM  Is This the Next Home-Run Biotech Stock? Motley Fool +7.10%
Jun-20-17 08:15AM  Featured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland Accesswire +7.43%
Jun-19-17 08:43AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:00AM  FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies PR Newswire
Jun-14-17 04:42PM  Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data Benzinga
Jun-13-17 07:15AM  Axovant reports 4Q loss Associated Press
07:00AM  Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates PR Newswire
Jun-06-17 07:30AM  Axovant Strengthens Executive Team with Key Management Appointments PR Newswire
07:30AM  Axovant Announces Changes to Board of Directors PR Newswire
May-31-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Apr-18-17 03:43PM  Axovant: A New CEO Doesn't Change Anything Motley Fool
Apr-17-17 04:15PM  Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares PR Newswire
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com +11.11%
Apr-12-17 08:37AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
08:20AM  Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2% Zacks
Apr-11-17 04:29PM  What's Got Axovant Sciences Jumping 10% Today? Motley Fool +9.22%
02:55PM  New Captain, Same Ship for Axovant Bloomberg
07:30AM  Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Accesswire
07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
07:00AM  Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares PR Newswire
06:00AM  The State of Play in Axovant Sciences Investopedia
12:20AM  [$$] The $400 Million Man The Wall Street Journal
Apr-10-17 04:30PM  Axovant CEO David Hung Promises To Invest $10 Million As Company Moves To Raise $100 Million Forbes +22.54%
04:15PM  Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives Investor's Business Daily
04:05PM  Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares PR Newswire
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VERNON W ANTHONYDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:08 PM
FALBERG KATHRYN EDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:07 PM
Hung DavidPrincipal Executive OfficerApr 17Buy18.54539,37510,000,013539,375Apr 19 04:06 PM
open in yahoo | open in reuters | open in google